Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about ESALF

Recent news which mentions ESALF

< Previous 1 2 Next >
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
Tickers BIIB ESALF ESALY
Tags BIIB Health Care Biotech
From Benzinga
Medicare unveils plan for coverage of new Alzheimer’s drugs
Tickers BIIB ESALF LLY
Tags ESALF LLY BIIB
From MarketWatch
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Tickers BIIB ESALF ESALY LLY
Tags Benzinga LLY Trading Ideas
From Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Tickers BIIB ESALF ESALY LLY
Tags Market News Alzheimer’s LLY
From Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Tickers ESALF ESALY MRK
Tags Benzinga MRK Market News
From Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
Tickers BIIB ESALF ESALY
Tags Alzheimer’s Market News Benzinga
From Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Tickers BIIB ESALF ESALY
Tags Benzinga ESALF Market News
From Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Tickers BIIB ESALF ESALY LLY
Tags ESALF Regulations ESALY
From Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Tickers BIIB ESALF ESALY
Tags Benzinga Market News BIIB
From Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Tickers BIIB ESALF ESALY
Tags ESALF ESALY Briefs
From Benzinga
The 7 Best Growth Stocks to Buy for February 2023
Tickers ACLS CPRX DAR ESALF
Tags ICLR ESALF ACLS
From InvestorPlace
New Alzheimer’s drug shows some promise, but has big price tag
Tickers BIIB ESALF
Tags ESALF JP:4523 BIIB
From MarketWatch
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Tickers BIIB ESALF ESALY
Tags Health Care BIIB Biotech
From Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
Tickers BIIB ESALF ESALY
Tags Health Care BIIB Biotech
From Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Tickers CPRX ESALF ESALY
Tags Small Cap Biotech CPRX
From Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Tickers BIIB ESALF ESALY
Tags Biotech Large Cap BIIB
From Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Tickers BIIB ESALF ESALY
Tags ESALF General News
From Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Tickers BIIB ESALF ESALY
Tags Large Cap Biotech BIIB
From Benzinga
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
Tickers BIIB ESALF LLY MOR
Tags ESALF PRTA CH:ROG
From MarketWatch
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Tickers BIIB ESALF ESALY MOR
Tags ESALF RHHBF Briefs
From Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Tickers BIIB ESALF ESALY LLY
Tags Biotech BIIB Health Care
From Benzinga
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
Tickers BIIB ESALF SPX
Tags ESALF SPX JP:4523
From MarketWatch
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Tickers ESALF ESALY MRK
Tags General ESALY Briefs
From Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Tickers ESALF ESALY LLY RHHBF
Tags Health Care Biotech Large Cap
From Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Tickers ESALF ESALY MRK
Tags MRK Market News Benzinga
From Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Tickers AMTI BIIB ESALF ESALY
Tags IBB RHHVF ESALY
From Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Tickers AGEN ARWR ATNX AVGR
Tags ATNX XENE General
From Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Tickers BIIB ESALF ESALY
Tags Alzheimer's disease Biotech BIIB
From Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
Tickers BIIB ESALF ESALY
Tags ESALF ESALY Briefs
From Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
Tickers ESALF ESALY MRK
Tags ESALF General ESALY
From Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.